Twist Bioscience Stock Tops Analyst Targets After Guidance Raise and Amazon Partnership
NEW YORK, April 15 —
Twist Bioscience raised guidance and landed an Amazon partnership. Shares jumped to $56.87, topping Barclays' freshly raised $55 price target.
- Barclays raised its TWST price target to $55. The stock already blew through it at $56.87.
- Forward P/E sits at -30.2x on $392mn trailing revenue. Profitability is a promise, not a fact.
- Next quarter's earnings will show whether the raised guidance and Amazon revenue hit the books.
What Actually Happened
Twist Bioscience makes synthetic DNA on a silicon-based platform. This week it got the analyst upgrade cycle every growth stock dreams about. The company lifted its own guidance. Barclays pushed its price target to $55. Guggenheim reiterated its rating and flagged the Amazon partnership as a new catalyst. The stock climbed on all three.
The Amazon tie-up is the detail that matters. Synthetic biology companies have spent years trying to turn Big Tech interest into recurring revenue. If Amazon is buying synthetic DNA at scale — for data storage or anything else — that's commercial validation worth more than any analyst note. Guggenheim clearly agrees.
The Catch
Two things should keep investors honest. First, insiders sold shares into the rally. Executives sell for all kinds of reasons, so that alone doesn't prove much. But a guidance raise paired with officers trimming their own stakes is a pattern worth flagging.
Second, the math is awkward. Barclays just lifted its target to $55, and the stock already trades at $56.87. When a stock outruns an upgrade on the day it prints, buyers are betting on more optimism than Wall Street will underwrite. The negative forward P/E confirms Twist is still burning cash. Trailing revenue of $392mn is real and growing, but this valuation needs the guidance raise to be a floor, not a ceiling.
Bottom Line
The story is better than it was a month ago. A guidance raise plus a credible tech partnership is the kind of one-two punch that moves a mid-cap biotech out of the "speculative" bucket and into the "show me" bucket. But a stock trading above its freshest price target tells you the easy move already happened. Watch next quarter's revenue. If it runs ahead of the new guidance, the re-rating continues. If it only meets the raised bar, this price has nowhere to go.
There's no existing Basis Report coverage for Twist Bioscience yet. Generate a full TWST report here to dig into the financials. For another mid-cap where a tech partnership rallied the stock past analyst targets, see our take on Lumen Technologies Jumped 4% on the AWS Deal.
Basis Report does not hold positions in securities discussed. This is not investment advice.